These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

799 related articles for article (PubMed ID: 29232467)

  • 1. Immunotherapy in ovarian cancer.
    Odunsi K
    Ann Oncol; 2017 Nov; 28(suppl_8):viii1-viii7. PubMed ID: 29232467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Therapy Opportunities in Ovarian Cancer.
    Kandalaft LE; Odunsi K; Coukos G
    Am Soc Clin Oncol Educ Book; 2020 May; 40():1-13. PubMed ID: 32412818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
    Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
    Front Immunol; 2018; 9():947. PubMed ID: 29770138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging immunotherapies in ovarian cancer.
    Ojalvo LS; Nichols PE; Jelovac D; Emens LA
    Discov Med; 2015 Sep; 20(109):97-109. PubMed ID: 26463091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Approaches for Immune Directed Treatment for Ovarian Cancer.
    Hardwick N; Frankel PH; Cristea M
    Curr Treat Options Oncol; 2016 Mar; 17(3):14. PubMed ID: 26942589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian Cancer Immunotherapy: Turning up the Heat.
    Ghisoni E; Imbimbo M; Zimmermann S; Valabrega G
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer.
    Chodon T; Lugade AA; Battaglia S; Odunsi K
    Hematol Oncol Clin North Am; 2018 Dec; 32(6):1025-1039. PubMed ID: 30390758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Past, present and future targets for immunotherapy in ovarian cancer.
    Schwab CL; English DP; Roque DM; Pasternak M; Santin AD
    Immunotherapy; 2014; 6(12):1279-93. PubMed ID: 25524384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunotherapy of patients with ovarian cancer.
    Hwu P; Freedman RS
    J Immunother; 2002; 25(3):189-201. PubMed ID: 12000860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in Ovarian Cancer.
    Wang W; Liu JR; Zou W
    Surg Oncol Clin N Am; 2019 Jul; 28(3):447-464. PubMed ID: 31079799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer.
    McGray AJR; Huang RY; Battaglia S; Eppolito C; Miliotto A; Stephenson KB; Lugade AA; Webster G; Lichty BD; Seshadri M; Kozbor D; Odunsi K
    J Immunother Cancer; 2019 Jul; 7(1):189. PubMed ID: 31315674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in ovarian cancer.
    Krishnan V; Berek JS; Dorigo O
    Curr Probl Cancer; 2017; 41(1):48-63. PubMed ID: 28169004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer.
    Nersesian S; Glazebrook H; Toulany J; Grantham SR; Boudreau JE
    Front Immunol; 2019; 10():1782. PubMed ID: 31456796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor infiltrating lymphocytes in ovarian cancer.
    Santoiemma PP; Powell DJ
    Cancer Biol Ther; 2015; 16(6):807-20. PubMed ID: 25894333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer.
    Chae CS; Teran-Cabanillas E; Cubillos-Ruiz JR
    Cancer Immunol Immunother; 2017 Aug; 66(8):969-977. PubMed ID: 28214928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunity and immune suppression in human ovarian cancer.
    Preston CC; Goode EL; Hartmann LC; Kalli KR; Knutson KL
    Immunotherapy; 2011 Apr; 3(4):539-56. PubMed ID: 21463194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted immune therapy of ovarian cancer.
    Knutson KL; Karyampudi L; Lamichhane P; Preston C
    Cancer Metastasis Rev; 2015 Mar; 34(1):53-74. PubMed ID: 25544369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint inhibitors in immunotherapy of ovarian cancer.
    Wang DH; Guo L; Wu XH
    Tumour Biol; 2015 Jan; 36(1):33-9. PubMed ID: 25409618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer.
    McGray AJR; Eppolito C; Miliotto A; Singel KL; Stephenson K; Lugade A; Segal BH; Keler T; Webster G; Lichty B; Kozbor D; Odunsi K
    Cancer Immunol Immunother; 2021 Dec; 70(12):3451-3460. PubMed ID: 33880648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.